DIRECTORIO DE BUFETES en la WEB: A | B | C | D | E | F | G | H | I-K | L | M | N | O | P | Q | R | S | T | U | V | W-Z |
Le enviamos regularmente las últimas noticias
Su Nombre:
Su Email:
INTERNATIONAL DEALS
Slaughter and May is advising GlaxoSmithKline (GSK) on the acquisition from UCB S.A. (UCB) of its current marketed product portfolio across certain territories in Africa, the Middle East, Asia Pacific and Latin America, for a cash consideration of €515 million. As part of the acquisition, GSK will acquire several leading pharmaceutical brands in a number of disease areas. These include Keppra, for the treatment of epilepsy, and Xyzal and Zyrtec for the treatment of allergic rhinitis. The acquisition which was announced on 23 January 2009 is expected to complete in late March. It follows the agreement GSK announced with South African-based pharmaceuticals company Aspen in July 2008, which significantly extended GSK’s pharmaceuticals portfolio in emerging markets, the acquisition of the Egyptian mature products business of Bristol Myers Squibb (BMS) in October 2008 and the acquisition of BMS Pakistan in December 2008. Simon Nicholls (partner), Adam Eastell (associate), Iqbal Hussain (associate); Competition: Bertrand Louveaux (partner), Steve Smith (associate); Intellectual Property: Susie Middlemiss (partner), Richard Smith (associate), Laura Hillier (associate), Louisa Christofidou (associate); Pensions and Employment: Sandeep Madugil (partner), Eleanor Hart (associate); Tax: Jeanette Zaman (partner), Dominic Robertson (associate), Max Mittasch (associate)
copyright, 2006 - Strong Element, S.L. - Peña Sacra 18 - E-28260 Galapagar - Madrid - Spain - Tel.: + 34 91 858 75 55 - Fax: + 34 91 858 56 97 - info@lawyerpress.com - www.lawyerpress.com - Aviso legal
